Wegovy, which contains the active ingredient semaglutide, is a medication used to support weight management for individuals who are clinically classified as obese or overweight. Since Wegovy’s initial appearance on the market, the standard maintenance dose has been 2.4 mg once weekly. However, recent clinical advancements from the manufacturer Novo Nordisk have spurred the development of the higher 7.2 mg dose to provide more weight-loss support for patients who need it. Like all medicines, especially weight loss medicines, the Wegovy 7.2 mg strength can cause side effects, and it is important to understand what these might be before considering moving up to this strength.
Table of Contents
Common Side Effects
Wegovy 7.2 mg works by activating GLP-1 receptors in the body to reduce appetite and slow digestion. Because of this, most side effects are related to the digestive system. The most frequently reported include:
- Nausea
- Vomiting
- Diarrhoea
- Constipation
- Abdominal pain or bloating
These side effects often occur when the dose is being increased. Many people find that symptoms improve once their body adjusts, especially after several weeks on the same dose.
Are Side Effects Worse With 7.2 mg?
Since the 7.2 mg strength delivers a higher amount of semaglutide than the currently approved 2.4 mg dose, some people may experience side effects more strongly. Clinical trials have shown that gastrointestinal symptoms remain the most common, but rates of discontinuation were slightly higher at 7.2 mg compared with lower doses. Most reactions were still considered mild to moderate in severity.
Less Common Side Effects
In addition to digestive issues, some people may experience:
- Headaches or fatigue
- Indigestion or reflux
- Injection site reactions (such as redness or itching)
As with all GLP-1 medications, there are also rare risks to be aware of, including pancreatitis, gallbladder problems, kidney issues, or worsening diabetic retinopathy in patients with type 2 diabetes. These require medical attention if suspected.
Safety and Monitoring
Anyone considering Wegovy 7.2 mg will be doing so under the guidance of our qualified clinical team at Pharmacy Planet. It is a higher dose, so close monitoring is crucial, especially during the transition from the original maintenance dose of 2.4mg, as this is three times the amount of medication. Patients should be advised to report severe or persistent symptoms immediately.
